Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

We hypothesize that allogeneic T cells genetically-engineered to be able to specifically recognize the CD19 protein that is expressed on most B-cell malignancies will be a potent and form of T cell therapy for patients with relapsed B-cell malignancies after allogeneic stem cell transplants. This work is now complete, and it has been published in Kochenderfer et al. Blood 2013 and Brudno et al. Journal of Clinical Oncology 2016. Starting in 2017 this project has focused on testing a less differentiated type of CAR T cells. These T cells are called stem memory T cells. This work is carried out in collaboration with another investigator, Luca Gatinonni. The goals of this work are to develop CAR T cells that have greater abilities to proliferate and survive after infusion into patients.